Tyrosinemia type II, also known as oculocutaneous tyrosinemia or Richner-Hanhart syndrome, is a rare genetic disorder that affects the body's ability to break down the amino acid tyrosine. This condition is inherited in an autosomal recessive manner, meaning that both parents must carry a mutated gene for their child to be affected.
Symptoms:
Individuals with tyrosinemia type II may experience a range of symptoms that primarily affect the eyes and skin. These symptoms can vary in severity and may include:
Treatment:
Currently, there is no cure for tyrosinemia type II. However, management of the condition focuses on reducing symptoms and preventing complications. This typically involves:
Prognosis:
The long-term outlook for individuals with tyrosinemia type II varies depending on the severity of symptoms and the effectiveness of management strategies. With proper treatment and adherence to dietary restrictions, many individuals can lead relatively normal lives. However, without appropriate care, severe eye complications and skin lesions can significantly impact quality of life.